2025
An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy
Schrank B, Wang Y, Wu A, Tran N, Lee D, Edwards J, Huntoon K, Dong S, Ha J, Ma Y, Grippin A, Jeong S, Antony A, Chang M, Kang M, Gallup T, Koong A, Li J, Yun K, Kim B, Jiang W. An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nature Cancer 2025, 6: 511-527. PMID: 40000910, DOI: 10.1038/s43018-025-00919-0.Peer-Reviewed Original ResearchConceptsAntibody-toxin conjugatesTumor cellsImmune recognition of tumor cellsEnhanced antigen cross-presentationRecognition of tumor cellsCancer cell phagocytosisTumor-derived antigensToxin listeriolysin OTumor-derived peptidesImproved animal survivalPromote immune recognitionCytosolic immune sensorsIntracellular bacterium Listeria monocytogenesTreatment in vivoTreating multiple cancersPhagocytosis checkpointsCheckpoint blockadeCancer immunotherapySignal CD47Listeriolysin OMetastatic breastMelanoma tumorsTherapeutic strategiesAnimal survivalCell phagocytosis
2024
Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors
Lim S, Lin Y, Lee J, Pedersen B, Stewart A, Scolyer R, Long G, Yang J, Rizos H. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors. EBioMedicine 2024, 107: 105308. PMID: 39216232, PMCID: PMC11402938, DOI: 10.1016/j.ebiom.2024.105308.Peer-Reviewed Original ResearchMelanoma cellsTranscriptional cell statesTreatment responseSingle-cell RNA sequencingResponse to MAPK inhibitorsPlasticity of melanoma cellsBRAF/MEK inhibitor treatmentImmunotherapy-resistant tumorsMelanoma Institute AustraliaNational Health and Medical Research Council of AustraliaImpact treatment responseMelanoma cell statesPro-inflammatory signalingNational Health and Medical Research CouncilCell statesPro-inflammatory IL6Melanoma tumorsHeterogeneous cancerInhibitor resistanceInhibitor treatmentMelanomaBRAF/MEKRNA sequencingMAPK inhibitorStudy treatment responses
2023
Tumor treatment by pHLIP-targeted antigen delivery
DuPont M, Visca H, Moshnikova A, Engelman D, Reshetnyak Y, Andreev O. Tumor treatment by pHLIP-targeted antigen delivery. Frontiers In Bioengineering And Biotechnology 2023, 10: 1082290. PMID: 36686229, PMCID: PMC9853002, DOI: 10.3389/fbioe.2022.1082290.Peer-Reviewed Original ResearchAnti-HA antibodiesAntigen deliveryHigh titersTumor cellsTriple-negative breast tumorsCancer cellsDifferent vaccination schemesNegative breast tumorsHA epitopeAntigen therapyImmunized miceImmune cellsNeo-antigensT cellsSignificant tumorsVaccination schemeViral infectionTherapeutic efficacyBreast tumorsHepatic clearanceImmune systemMelanoma tumorsTumorsPeptide epitopesAdjuvant
2021
3D Model of the Early Melanoma Microenvironment Captures Macrophage Transition into a Tumor-Promoting Phenotype
Pizzurro GA, Liu C, Bridges K, Alexander AF, Huang A, Baskaran JP, Ramseier J, Bosenberg MW, Mak M, Miller-Jensen K. 3D Model of the Early Melanoma Microenvironment Captures Macrophage Transition into a Tumor-Promoting Phenotype. Cancers 2021, 13: 4579. PMID: 34572807, PMCID: PMC8471848, DOI: 10.3390/cancers13184579.Peer-Reviewed Original ResearchTumor-associated macrophagesMelanoma tumor microenvironmentTumor microenvironmentTumor-promoting phenotypeAnti-tumor activityImmunosuppressive stateDisease progressionCo-culture systemImmune responseImmune activitySecretion profileDirect cell-cell interactionsMelanoma tumorsStromal componentsMacrophage transitionStromal cellsTumor cellsMelanoma cells5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Tian J, Zhang D, Kurbatov V, Wang Q, Wang Y, Fang D, Wu L, Bosenberg M, Muzumdar MD, Khan S, Lu Q, Yan Q, Lu J. 5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING. The EMBO Journal 2021, 40: embj2020106065. PMID: 33615517, PMCID: PMC8013832, DOI: 10.15252/embj.2020106065.Peer-Reviewed Original ResearchConceptsAnti-tumor immunityTumor burdenSubsequent type I interferon productionHigh STING expressionIntratumoral T cellsT-cell depletionType I interferon productionI interferon productionLoss of STINGImmunocompetent hostsColorectal specimensT cellsSTING expressionBetter survivalHigh doseTherapeutic effectivenessHuman colorectal specimensMelanoma tumorsInterferon productionChemotherapeutic drugsMurine colonImmunityEfficacyStingsColon
2013
Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
Beard R, Abate-Daga D, Rosati S, Zheng Z, Wunderlich J, Rosenberg S, Morgan R. Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy. Clinical Cancer Research 2013, 19: 4941-4950. PMID: 24021875, PMCID: PMC3778100, DOI: 10.1158/1078-0432.ccr-13-1253.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, NeoplasmBiomarkers, TumorFemaleFlow CytometryGene Expression ProfilingHumansImmunoenzyme TechniquesImmunotherapyMaleMelanomaMiddle AgedNanotechnologyReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSkinTumor Cells, CulturedYoung AdultConceptsTumor samplesTarget antigenNormal tissuesTreatment of metastatic cancerPotential tumor antigensStudied tumor samplesMetastatic melanoma tumorsSuccess of immunotherapyPercentage of tumorsPotential target antigensTreatment of melanomaCell linesTissue samplesMelanoma cell linesMelanoma tumor samplesTissue gene expressionAnalysis of cell linesAdoptive immunotherapyMelanoma immunotherapyTumor antigensPotential immunotherapyMelanoma tumorsMetastatic cancerImmunotherapyDifferent malignancies
2002
COMMENTARY Pigmentation in Melanomas: Changes Manifesting Underlying Oncogenic and Metabolic Activities
Halaban R. COMMENTARY Pigmentation in Melanomas: Changes Manifesting Underlying Oncogenic and Metabolic Activities. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2002, 13: 3-8. PMID: 12201672, DOI: 10.3727/096504002108747908.Peer-Reviewed Original ResearchConceptsMelanocyte-specific gene expressionTranscription factor MITFDownregulation of tyrosinaseEpigenetic levelV-ATPaseRate-limiting enzymeTranscriptional activityGene expressionAcidified microenvironmentsAmelanotic melanoma cellsC-MycActivity of tyrosinaseEnhanced glycolysisMelanin synthesisExtracellular acidificationMelanoma tumorsTYR activityMelanoma cellsMetabolic activityPigmentationAnaerobic conditionsTyrosinase activityMetastatic melanocytic lesionsMetabolic changesTyrosinase
1999
Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement
Wang B, Chen Y, Ayalon O, Bender J, Garen A. Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 1627-1632. PMID: 9990075, PMCID: PMC15540, DOI: 10.1073/pnas.96.4.1627.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBase SequenceCell LineCells, CulturedCHO CellsChondroitin Sulfate ProteoglycansChromatography, LiquidComplement System ProteinsCricetinaeCytotoxicity, ImmunologicDrosophila melanogasterEndothelium, VascularHumansImmunoconjugatesImmunoglobulin FragmentsImmunoglobulin GImmunoglobulin Variable RegionKiller Cells, NaturalMass SpectrometryMelanomaMolecular Sequence DataRestriction MappingSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTransfectionTumor Cells, CulturedConceptsHuman melanoma cellsNatural killer cellsNK cellsMelanoma cellsKiller cellsChondroitin sulfate proteoglycanCytolytic responsesMost human melanoma cellsTumor cellsVaccinated melanoma patientsCultured human melanoma cellsCytolytic immune responseFusion phage librarySpecific cytolytic responseMelanoma-associated chondroitin sulfate proteoglycanHuman single-chain FvSulfate proteoglycanMelanoma patientsSpecific lysisImmune responseMelanoma tumorsComplement cascadeTargeted tumor cellsImmunoconjugatesHuman IgG1
1992
Assignment of a Locus for Familial Melanoma, MLM, to Chromosome 9p13-p22
Cannon-Albright L, Goldgar D, Meyer L, Lewis C, Anderson D, Fountain J, Hegi M, Wiseman R, Petty E, Bale A, Olopade O, Diaz M, Kwiatkowski D, Piepkorn M, Zone J, Skolnick M. Assignment of a Locus for Familial Melanoma, MLM, to Chromosome 9p13-p22. Science 1992, 258: 1148-1152. PMID: 1439824, DOI: 10.1126/science.1439824.Peer-Reviewed Original ResearchConceptsMelanoma susceptibility locusSusceptibility lociFamilial melanoma susceptibilityInterferon alpha genesFamilial melanomaMultipoint linkage analysisShort tandem repeat markersRepeat markersTandem repeat markersChromosomal regionsGenetic markersLinkage analysisLociSomatic lossMelanoma susceptibilityMelanoma tumorsGermline deletionChromosome 9p21Maximum location scoreHomozygous deletionCritical roleCandidate regionsDeletionUtah kindredsChromosomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply